Methacrylic Acid

Methacrylic Acid

SCHEMBL1148753

C=C(C)C(=O)[O-].C=C(C)C(=O)[O-].CC[O-].CC[O-].[Ti+4]

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CA4 P22748 2/20 0.42
CA1 P00915 2/20 0.39
TDP1 Q9NUW8 2/20 0.38
ALDH1A1 P00352 2/20 0.35
FFAR3 O14843 2/20 0.35
HDAC3 O15379 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
THRB P10828 1/20 0.33
TSHR P16473 2/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methacrylic Acid SCHEMBL1148756 0.94 CA4 (0.42) CA4CA1TDP1ALDH1A1FFAR3
Methacrylic Acid SCHEMBL1148657 0.89 CA4 (0.38) CA4CA1TDP1FFAR3HDAC3
Methacrylic Acid SCHEMBL819743 0.87 CA4 (0.53) CA4CA1TDP1ALDH1A1FFAR3
Methacrylic Acid SCHEMBL15254680 0.86 TDP1 (0.40) CA4CA1TDP1ALDH1A1FFAR3
Methacrylic Acid SCHEMBL1919175 0.84 CA4 (0.50) CA4CA1TDP1ALDH1A1FFAR3
Methacrylic Acid SCHEMBL28124744 0.84 CA4 (0.50) CA4CA1TDP1ALDH1A1FFAR3
Methacrylic Acid SCHEMBL59390 0.84
Methacrylic Acid SCHEMBL19384595 0.84 CA4 (0.57) CA4CA1TDP1ALDH1A1FFAR3
Methacrylic Acid SCHEMBL1148660 0.83 CA4 (0.38) CA4CA1TDP1FFAR3HDAC3
Methacrylic Acid SCHEMBL1225172 0.83 CA4 (0.38) CA4CA1TDP1FFAR3HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340450-B2 Etching method for surface structuring SCHOTT AG (DE) 2016-05-17 US disclosed
US-9142800-B2 Substrate glass for LEDs with layer containing scattering particles and method for production thereof SCHOTT AG (DE) 2015-09-22 US disclosed
US-20120128938-A1 ETCHING METHOD FOR SURFACE STRUCTURING SCHOTT AG (DE) 2012-05-24 US disclosed
US-20110045259-A1 SUBSTRATE GLASS FOR LEDS WITH LAYER CONTAINING SCATTERING PARTICLES AND METHOD FOR PRODUCTION THEREOF SCHOTT AG 2011-02-24 US disclosed
US-20110039079-A1 STRUCTURED SUBSTRATE GLASS FOR LED'S AND METHOD FOR PRODUCTION THEREOF SCHOTT AG 2011-02-17 US disclosed
US-6835792-B2 A metal aliphatic acryl alkoxide M(-OR1-CO-CR2=CR3R4)n is hydrolyzed into a mixture of metal oxide nanoparticles and acrylate monomer; free radical polymerization to form a matrix containing well-dispersed metal oxide naonoparticles; films POLE-CHIC CORPORATION (TW) 2004-12-28 US disclosed
US-6492540-B1 ENCLOSED ARE HIGH REFRACTIVE INDEX AND LOW BIREFRINGENCE ORGANIC/INORGANIC HYBRID MATERIALS USEFUL FOR OPTICAL APPLICATIONS. THEY ARE PREPARED FROM SOLVENTLESS METAL ALIPHATIC ACRYL ALKOXIDES. THE METAL ACRYL ALKOXIDES ARE POLE-CHIC CORPORATION (TW) 2002-12-10 US disclosed
US-20020128502-A1 Solventless nontoxic high refractive index and low birefringence organic/inorganic hybrid materials POLE-CHIC CORPORATION 2002-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128502-A1 Solventless nontoxic high refractive index and low birefringence organic/inorganic hybrid materials ADH1A, ALDH3A1, ALDH1A2 CA4 174/4885CA1 113/4885TDP1 2610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.